GGL-17227-07137
4 vaccinations
4 coded responses
46 check-ins
4 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 986 / WA
- Registered
- 2021-03-13
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-13
Registered in v-safe
-
2021-03-13
Dose 1 — Pfizer-BioNTech
- 2021-03-13
- 2021-03-14
- 2021-03-15
- 2021-03-16
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-20
- 2021-03-27
-
2021-04-03
Dose 2 — Pfizer-BioNTech
- 2021-04-03
-
2021-04-04
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Headache, Fatigue or tirednessAdult check-in
-
2021-04-05
Health check-in — days 1–6 daily, dose 2Feeling: Good · Headache, Fatigue or tirednessAdult check-in
-
2021-04-06
Survey response — days 1–6 daily, dose 2MedDRA: Injection site bruising — Feeling: GoodFree text: Bruising at injection siteMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-07
- 2021-04-08
- 2021-04-09
- 2021-04-10
- 2021-04-17
-
2021-04-24
Survey response — day 21, dose 2MedDRA: Heavy menstrual bleeding — Feeling: GoodFree text: Abnormally long menstrual cycle3 days longer.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-05-01
- 2021-05-08
- 2021-05-15
- 2021-07-04
- 2021-10-02
-
2021-10-17
Dose 3 — Pfizer-BioNTech
- 2021-10-17
-
2021-10-19
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
-
2021-10-20
Survey response — days 1–6 daily, dose 3MedDRA: Vulvovaginal mycotic infection — Feeling: FairFree text: Vaginal yeast infectionMedDRA releases: 2024-11 · check-in free text available
-
2021-10-22
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
- 2021-10-23
- 2021-10-26
- 2021-10-31
- 2021-11-07
- 2021-11-14
- 2021-11-21
- 2021-11-28
- 2022-01-16
- 2022-04-17
-
2022-09-26
Dose 4 — Pfizer-BioNTech
- 2022-10-02
- 2022-10-03
- 2022-10-11
- 2022-10-19
- 2022-10-24
-
2022-11-01
Survey response — day 35, dose 4MedDRA: Oropharyngeal pain, Rhinorrhoea, Sneezing — Feeling: Poor · Be unable to work or attend schoolFree text: Runny nose, sneezing, sore throatMedDRA releases: 2024-11 · check-in free text available
- 2022-11-07
- 2022-12-26
- 2023-03-27
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-13 | Pfizer-BioNTech | |
| 2 | 2021-04-03 | Pfizer-BioNTech | |
| 3 | 2021-10-17 | Pfizer-BioNTech | No |
| 4 | 2022-09-26 | Pfizer-BioNTech | No |
Free text
Release 7 — days 1–6 daily, dose 2
Systemic reaction (other): Bruising at injection site
Release 7 — day 21, dose 2
Symptoms: Abnormally long menstrual cycle3 days longer.
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): Vaginal yeast infection
Release 12 — day 35, dose 4
Symptoms: Runny nose, sneezing, sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Heavy menstrual bleeding | ✓ | ✓ | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Sneezing | · | · | ✓ |
| SRO | Injection site bruising | ✓ | ✓ | ✓ |
| SRO | Vulvovaginal mycotic infection | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release